GlassScriptPhysician profile
Lori Jill Goldstein
NPI 1598735219
$128,162.98
in general payments reported to CMS, 2019-2025
15 companies · $3,596 in 2025
The $3,596 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $19K · 2021: $17K · 2022: $26K · 2023: $7,021 · 2024: $7,967 · 2025: $3,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Grant: $350 · Food and Beverage: $81.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,152.50 |
| Grant | $350.00 |
| Food and Beverage | $81.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $56,912.59 | 2019-2025 | Enhertu |
| Mylan INC. | $15,287.61 | 2019 | |
| Merck Sharp & Dohme LLC | $10,329.34 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $7,910.00 | 2020-2024 | |
| Gilead Sciences, INC. | $5,963.52 | 2021-2022 | |
| Immunomedics, INC. | $5,637.50 | 2020 | |
| Genentech USA, INC. | $5,098.59 | 2019 | |
| Genentech, INC. | $4,368.92 | 2019-2024 | Herceptin, Tecentriq, Perjeta |
| Eisai Co., LTD. | $3,915.00 | 2021 | |
| Ge Healthcare | $3,738.00 | 2022 | |
| Radius Health, INC. | $3,650.29 | 2019 | |
| Amgen INC. | $3,300.00 | 2019 | |
| Eisai INC. | $2,000.00 | 2019 | |
| Pfizer INC. | $51.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.